Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules

Geneviève Marcoux(Centre hospitalier universitaire de Québec), Audrée Laroche(Centre hospitalier universitaire de Québec), Stephan Hasse(Centre hospitalier universitaire de Québec), Marie Bellio(Centre hospitalier universitaire de Québec), Maroua Mbarik(Centre hospitalier universitaire de Québec), Marie Tamagne(Inserm), Isabelle Allaeys(Centre hospitalier universitaire de Québec), Anne Zufferey(Centre hospitalier universitaire de Québec), Tania Lévesque(Centre hospitalier universitaire de Québec), Johan Rebetz(Lund University), Annie Karakeussian-Rimbaud(Translational Research in Oncology), Julie Turgeon(Translational Research in Oncology), Sylvain Bourgoin(Centre hospitalier universitaire de Québec), Hind Hamzeh‐Cognasse(Université Claude Bernard Lyon 1), Fabrice Cognasse(Université Claude Bernard Lyon 1), Rick Kapur(Sanquin), John W. Semple(University of Toronto), Marie‐Josée Hébert(Translational Research in Oncology), France Pirenne(Inserm), Herman S. Overkleeft(Netherlands Metabolomics Centre), Bogdan I. Florea(Netherlands Metabolomics Centre), Mélanie Dieudé(Translational Research in Oncology), Benoît Vingert(Inserm), Éric Boilard(Centre hospitalier universitaire de Québec)
Blood
July 22, 2021
Cited by 88Open Access
Full Text

Abstract

In addition to their hemostatic role, platelets play a significant role in immunity. Once activated, platelets release extracellular vesicles (EVs) formed by the budding of their cytoplasmic membranes. Because of their heterogeneity, platelet EVs (PEVs) are thought to perform diverse functions. It is unknown, however, whether the proteasome is transferred from platelets to PEVs or whether its function is retained. We hypothesized that functional protein processing and antigen presentation machinery are transferred to PEVs by activated platelets. Using molecular and functional assays, we found that the active 20S proteasome was enriched in PEVs, along with major histocompatibility complex class I (MHC-I) and lymphocyte costimulatory molecules (CD40L and OX40L). Proteasome-containing PEVs were identified in healthy donor blood, but did not increase in platelet concentrates that caused adverse transfusion reactions. They were augmented, however, after immune complex injections in mice. The complete biodistribution of murine PEVs after injection into mice revealed that they principally reached lymphoid organs, such as spleen and lymph nodes, in addition to the bone marrow, and to a lesser extent, liver and lungs. The PEV proteasome processed exogenous ovalbumin (OVA) and loaded its antigenic peptide onto MHC-I molecules, which promoted OVA-specific CD8+ T-lymphocyte proliferation. These results suggest that PEVs contribute to adaptive immunity through cross-presentation of antigens and have privileged access to immune cells through the lymphatic system, a tissue location that is inaccessible to platelets.


Related Papers

No related papers found

Powered by citation graph analysis